Gonadotropin‐releasing hormone (GnRH) analogues for premenstrual syndrome (PMS)

摘要: Premenstrual syndrome (PMS) is a disorder affecting large numbers of women, characterized by set of symptoms that occur during the second, or luteal, half the menstrual cycle following ovulation. It occurs between 14th and 28th day an idealized 28 day (see Figure 1, 2, 3). Symptoms disappear by end menstruation do not recur before ovulation, giving symptom-free interval at least one week. PMS cyclical and in most cycles (O’Brien 2011), least 20% adolescents experience moderate-to-severe premenstrual symptoms are associated with functional impairment (Rapkin 2008). This condition often begins adolescence the establishment normal ovulatory cycles, however the underlying pathophysiology has yet to be determined. It important to assess confirm diagnosis initiation of therapy, especially psychotropic therapies, due possibly harmful side effect profile for compared adults. The diagnosis premenstrual (PMD) requires medical and psychological history physical examination, but it the daily prospective charting two cycles that will clearly determine if related PMS or another underlying medical psychiatric diagnosis. The number types less important than timing (ISPMD 2011). marked variety emotional, physical behavioural symptoms. The typically include irritability, depression, mood swings, bloating, breast tenderness and sleep disturbances (Gianetto-Berruti 2002; O’Brien 2003; Johnson 2004; Panay 2005). A severe form known as dysphoric (PMDD) causes significant Gonadotropin-releasing hormone (GnRH) analogues (Protocol) 1. distress interferes functioning. PMDD comprised of cluster affective, somatic symptoms recurring monthly during luteal phase cycle. The affects 3% 8% menstruating women represents the more disabling spectrum PMDs (DSM-V 2013).